Cesar A. Arias MD PhD
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Mauris sollicitudin elit a fermentum cursus. Sed eget urna suscipit metus euismod aliquet quis in est.
A primary goal of the ARLG is to train the next generation of researchers who will help reduce the public health threat of antibacterial resistance.
LEARN MORELorem ipsum dolor sit amet, consectetur adipiscing elit. Mauris sollicitudin elit a fermentum cursus. Sed eget urna suscipit metus euismod aliquet quis in est.
Rapid diagnostic PCR test to detect carbapenem-resistant organisms (CRO) directly in respiratory and urine samples in less than 1 hour (Diagnostic)
Vancomycin-resistant ENterococci OUtcomes Study
TITLEProspective Evaluation of Clinical Outcomes of Cancer Patients with Vancomycin-Resistant Enterococcus faecium (VRE) Bacteremia
DESCRIPTION
Prospective study in cancer patients 18 years of age and older to evaluate the outcomes of patients with Vancomycin-Resistant Enterococcus faecium (VRE) bloodstream infections (BSIs) treated with Daptomycin (DAP) to compare clinical outcomes stratifying by minimum inhibitory concentration (MIC).
Ceftriaxone Breakpoint
TITLEMulti-center gram negative database to establish clinically relevant antibiotic breakpoint interpretive criteria for Ceftriaxone
DESCRIPTION
A retrospective, observational propensity score-matched study of patients 18 years or older with monomicrobial Gram-negative bacteremia with the primary objective being:
to compare clinical outcomes of adult patients with Gram-negative bacteremia with organisms with minimum inhibitory concentrations between 4-8 µg/ml who received ceftriaxone compared with broader-spectrum antibiotic agents